Blood test guides breast cancer treatment in new trial
NCT ID NCT07335081
First seen Jan 12, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This study compares two different drug combinations given before surgery for early or locally advanced HER2-positive breast cancer. About 60 adults will be randomly assigned to receive either pyrotinib plus trastuzumab and docetaxel or pertuzumab plus trastuzumab and docetaxel. Researchers will use a blood test to measure tumor DNA and see which combination clears cancer cells faster.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.